ArticleTherapeutic advances in hematology2022

A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy.

Guangxin Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.